Biogen jumps on strong MS drug data: Sanofi's Lemtrada significant improvement ... The Pharma Letter Biogen and partner Abbott Laboratories (NYSE: ABT) also announced additional results from the SELECT Phase IIb trial, the first of two registrational studies designed to evaluate the investigational compound daclizumab high-yield process (DAC HYP) in ... |
